Federal update: DOJ partially rescheduled medical cannabis to Schedule III (April 28, 2026 final order). State-licensed medical operators may apply for expedited DEA registration through June 27, 2026; DEA hearing on full rescheduling set for June 29, 2026.

CAOA

The Cannabis Administration and Opportunity Act is comprehensive federal reform legislation first introduced in 2022 by Senate Majority Leader Chuck Schumer (D-NY) with Sens. Ron Wyden (D-OR) and Cory Booker (D-NJ). CAOA would deschedule cannabis from the CSA; transfer primary federal regulatory authority to FDA (with TTB handling taxation); impose a federal excise tax rising from 5% to 25%; expunge federal cannabis convictions; create an Opportunity Trust Fund financed by excise-tax revenue to support social-equity and community-reinvestment programs; and regulate CBD in dietary supplements and foods. CAOA is more comprehensive than the MORE Act, adding a detailed federal market framework. S. 4226 was reintroduced in the 118th Congress on May 1, 2024, with 18 cosponsors; it did not advance. As of April 2026, CAOA has not been reintroduced in the 119th Congress and is effectively dead as a near-term vehicle — with Schumer now Senate Minority Leader, no Republican co-sponsor, and no committee pathway in the Republican-controlled Senate. Booker and Wyden remain vocal federal-reform advocates but have not filed a successor bill. *→ See also: MORE Act, Descheduling, FDA